Simeon George

Dr. Simeon J.
George is an Independent Director at Nkarta, Inc., a Lead Independent Director at Design Therapeutics, Inc., a CEO & Managing Partner at SR One Capital Management LP, an Independent Director at CRISPR Therapeutics AG and a Chief Executive Officer at GSK Equity Investments Ltd. He is on the Board of Directors at Nkarta, Inc., Design Therapeutics, Inc., CRISPR Therapeutics AG, eFFECTOR Therapeutics Operations, Inc., Bird Rock Bio Sub, Inc., Auxogyn, Inc., Battersea Biotech, LLC, Rezo Therapeutics, Inc. and Simcha Therapeutics, Inc. Dr. George was previously employed as an Independent Non-Executive Director by Turning Point Therapeutics, Inc., an Independent Director by HTG Molecular Diagnostics, Inc., an Independent Director by Principia Biopharma, Inc., an Independent Director by Genocea Biosciences, Inc., an Associate by Goldman Sachs & Co. LLC, and a Principal by Merrill Lynch & Co., Inc. /Old/.
He also served on the board at Progyny, Inc., Semprus BioSciences Corp.
and Simcha Therapeutics Holding Co. LLC.
He received his undergraduate degree from The Johns Hopkins University, an MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from the University of Pennsylvania Medical Center.